Latest news with #Cencora
Business Wire
a day ago
- Business
- Business Wire
Good Neighbor Pharmacy Celebrates Independent Community Pharmacy Excellence at ThoughtSpot 2025
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora, brought together more than 4,000 community pharmacy owners, industry experts and partners for its flagship annual tradeshow and conference, ThoughtSpot. Now in its 14th year, ThoughtSpot serves as a celebration of Good Neighbor Pharmacy and its member pharmacies, recognizing their unwavering commitment to improving community health and advancing the future of pharmacy. The four-day event, held at the MGM Grand in Las Vegas, provided attendees with an opportunity to connect and explore programs and resources designed to help pharmacists grow their business, enhance patient care and navigate challenges. Programming focused on key initiatives and solutions to support the sustainability of independent pharmacy, with a specific focus on the importance of advocacy to advance pharmacy priorities and opportunities to evolve and expand services. 'ThoughtSpot celebrates the essential role community pharmacies play as accessible healthcare destinations while giving us the opportunity to connect with our Good Neighbor Pharmacy members, learn from their successes and challenges, and collaborate as we navigate the evolving pharmacy landscape,' said Tim Cernohous, SVP & President of Community Retail and Long-Term Care Pharmacy at Cencora. 'Pharmacists are facing increasing pressures, and our research shows that patients' needs are shifting – they want the convenience of a digitally enhanced customer experience with traditional in-person touchpoints, including access to a pharmacist. 'We are dedicated to supporting customers as they work to achieve an omni-channel experience, integrating digital enhancements with the benefits of in-person interaction to help pharmacies elevate their customer experience. With personalized coaching, data-driven insights and innovative tools, Good Neighbor Pharmacy is here to support its members every step of the way in shaping the future of pharmacy.' During ThoughtSpot, the 2025 Good Neighbor Pharmacy Champion Awards winners were announced, honoring three pharmacies for exceptional leadership in advocacy, clinical care and storytelling. The awards celebrate pharmacies that go above and beyond to advance the profession, improve patient care and inspire others, underpinning the critical role they play as accessible sites of care in their communities. This year's winners are: 2025 Advocacy Champion: The Apothecary Shoppe of Salt Lake City, Utah was honored as the 2025 Advocacy Champion for the exceptional leadership of its owner and pharmacist, Kevin DeMass, whose unwavering dedication to advocating for independent pharmacies and meaningful healthcare reform at the local, state and federal levels has made a profound impact. Through his tireless efforts, DeMass has worked to safeguard patient access to care and ensure the long-term success of the profession, inspiring others across the industry to join in shaping a stronger future for independent pharmacy. 2025 Clinical Care Champion: McDowell's Pharmacy of Scotland Neck, N.C., led by owner and fourth-generation pharmacist Thomas McDowell, was chosen as the 2025 Clinical Care Champion for its century-long commitment to serving the rural community of Scotland Neck. In addition, the pharmacy's innovative approach to improving health outcomes in a medically underserved rural community through pharmacist-led clinical services, including a successful Remote Patient Monitoring program, has helped transform chronic disease management for patients with hypertension and diabetes. 2025 Storytelling Champion: Cypress Wellness Pharmacy of Fort Myers, Fla., led by owner and pharmacist, Justin Ceravolo, was chosen as the 2025 Storytelling Champion for its innovative approach to reaching customers through strategic marketing. In addition, the pharmacy has excelled at tailoring its services to meet the evolving needs of the Fort Myers community, expanding from a traditional focus on older adults to offering family-friendly care, holistic wellness options and even pet medications to serve a more diverse audience and cement the pharmacy as a cornerstone for care. 'Kevin, Thomas and Justin, along with their peers that make up Good Neighbor Pharmacy, are true champions of their communities' health,' said Jenni Zilka, SVP, Community & Specialty Pharmacy and President of Good Neighbor Pharmacy. 'It is a privilege to stand alongside these independent pharmacies and support them in navigating unique industry challenges, helping them expand their services, strengthen their businesses and continue to provide high-quality care to their patients. ThoughtSpot honors all we have accomplished as partners and our commitment to building a sustainable future for independent pharmacy together.' Good Neighbor Pharmacy 's ThoughtSpot will be held next summer in Orlando, Fla. For more information on ThoughtSpot, please visit About ThoughtSpot ThoughtSpot is an annual conference and trade show hosted by Good Neighbor Pharmacy and powered by Cencora, which aims to equip independent pharmacists with practices and resources they can use to transform their businesses to improve profitability and maintain their position as a vital source of patient care in their local communities. For more information on ThoughtSpot, please visit About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at
Yahoo
12-07-2025
- Business
- Yahoo
Cencora, Inc. (COR): If It Was Down, I'd Say 'Double Down And Buy,' Says Jim Cramer
We recently published . Cencora, Inc. (NYSE:COR) is one of the stocks Jim Cramer recently discussed. Cencora, Inc. (NYSE:COR) is an American pharmaceutical and healthcare services provider. It is a rare stock in its peers that is in the green this year. Cencora, Inc. (NYSE:COR)'s shares have gained 32.30% year-to-date as the firm has benefited from being insulated against tariffs and the Most Favored Nation drug policy. The strong backdrop has also allowed it to raise its earnings guidance. In May, Cencora, Inc. (NYSE:COR) raised its profit per share guidance to $15.70 and $15.95 from an earlier $15.30 to $15.60. In his comments, Cramer shared that he'd buy the stock even if it dipped by 50%: 'No I mean look it's not the hospitals which always win and it's certainly not the middlemen. I mean if you told me Cencora was down 50%, I'd say why don't you double down and buy a lot.' Previously, the CNBC host discussed Cencora, Inc. (NYSE:COR) and its peers in detail: 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… The last quarter from the major drug distributors came from McKesson, and that was last Thursday night, which delivered yet another very strong set of numbers… Like the others. McKesson had a top-line miss, in this case, actually a pretty sizable one, but still delivered a significant earnings beat, and gave a higher-than-expected full-year earnings forecast in a vacuum. I think the McKesson quarter was strong enough to spark a nice rally for the stock last Friday. But we don't live in a vacuum, do we?… The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what's known as the Most-Favored-Nation pricing for Medicare… While we acknowledge the potential of COR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
08-07-2025
- Business
- Forbes
The Best 4 Healthcare Stocks To Buy Now In A Growing Sector
The relatively high dividends paid by some of these companies may prove worth the uncertain revenue ... More impact of Medicaid cuts. The healthcare sector is one of the largest in the U.S., with spending expected to account for 20% of the American economy as it reaches $5.2 trillion in 2025, according to NerdWallet. But the healthcare sector is likely to suffer considerably in the wake of the passage into law of the so-called Big Beautiful Bill. The industry's pain will result from a roughly $1 trillion reduction in Medicaid spending through 2034, according to the Congressional Budget Office. These cuts are likely to cause widespread pain. For example, 15.9 million Americans could lose Medicaid coverage, according to the Urban Institute. Hospitals' expenses for Medicaid patients could fall by $37 billion, estimated the Commonwealth Fund; to offset the lower revenue, hospitals, nursing homes, and doctors' offices could eliminate 477,000 jobs, according to the American Association of Medical Colleges. And many rural hospitals may be forced to close, forcing patients to travel further for care, noted the American Hospital Association. Nevertheless, the growth of companies providing high-value solutions to painful problems whose business models are relatively impervious to Medicaid cuts could provide attractive opportunities for investors. 4 Top Healthcare Stocks to Buy Now Healthcare consists of interconnected industries including the following: From this sector, the following stocks stand out. 1. Cardinal Health (CAH) Dublin, Ohio-based Cardinal Health distributes pharmaceuticals and medical products to more than 100,000 locations – controlling roughly 50% share of the market. Cardinal Health's stock rise can be attributed to a 2% boost, to $8.18, in analysts' 2025 consensus earnings per share due to stronger-than-expected growth and profitability in the company's pharmaceutical distribution and medical products segments, according to AInvest. Moreover, the stock could rise should the company report better than expected second quarter 2025 earnings. Due to Cardinal Health's 'cost discipline, supply chain stability, and rising demand for healthcare services post-pandemic,' analysts anticipate the company will report EPS of $2.04 – two cents above the Zacks consensus. Cardinal Health is on my list because investors have recognized the company is improving its operations, and many anticipate the company will exceed investor expectations. If demand remains strong and profitability rises, its shares could rise more. Medicaid cuts pose a significant risk to the healthcare sector, including Cardinal Health. Yet the company's diversified business model could enable it to withstand the worst damage from these cuts, AInvest reports. 2. Cencora (COR) Conshohocken, Pennsylvania-based Cencora – formerly known as AmerisourceBergen – is a drug wholesaler and contract research organization. Cencora's stock rise is likely due to the company's faster than expected growth in the first quarter of 2025. This growth resulted from higher unit volume, a boost in demand for diabetes and weight loss drugs, and a 2% increase, to $15.83, in the company's fiscal year 2025 earnings per share guidance, according to StockTwits. Although the pharmaceuticals distribution industry is intensely competitive, Cencora is expected to deliver solid profit growth and to exceed investor expectations. Specifically, investors anticipate the company's profits will rise 12.8% over the next five years in the wake of delivering 6% better than expected EPS for each of 'the trailing four quarters,' noted Zacks. I included Cencora due to its track record of beating investor expectations. However, Medicaid cuts could reduce drug sales as millions of Americans lose their Medicaid coverage – thus cutting into Cencora's revenues, noted AInvest. However, the company's focus on growing areas like specialty pharmaceuticals and its acquisition of a retinal care company could help offset the likely negative effects of Medicaid policy changes, according to Zacks. 3. Hinge Health (HNGE) San Francisco-based Hinge Health develops healthcare software for musculoskeletal care, acute injury, chronic pain and post-surgical rehabilitation. The company's stock market rise flowed from its torrid revenue growth – up 420% in the quarter ending in March, according to Google Finance. Hinge Health stock rose 23% after the company's May 2025 initial public offering. The stock is propelled by strong investor confidence in the company's digital musculoskeletal care platform and positive financial performance, according to BusinessInsider. Hinge Health is on my list for these same reasons. What's more, since the company primarily targets self-insured employers and is partnering with major health plans to expand into the Medicare Advantage market, this diversification could mitigate the pain of Medicaid cuts, noted AlphaSense. Nevertheless, Hinge Heath's stock price will likely rise only if the company beats expectations and raises guidance when the company next reports quarterly earnings. 4. Gilead Sciences (GILD) Foster City, California-based Gilead Sciences researches and develops antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza and COVID-19. Gilead's stock rise resulted from expectations-beating earnings in the first quarter, coupled with an optimistic forecast for 2025 EPS due to strong sales of existing products and new treatments, according to Reuters. In addition, the company's 99.9% effective HIV drug Sunienca received regulatory approval in the U.S. and Europe. Gilead is on my list because of its strong growth and bright prospects. However, since about 25% of the company's revenue is exposed to Medicaid – notably to its HIV drug Biktarvy – the Medicaid cuts could reduce the company's total revenue by 1% to 2%, according to Fierce Pharma. Bottom Line Healthcare is a huge, complex industry. Medicaid cuts could take a sizable bite out of many industry participants' revenue. The four companies described above – Cardinal Health, Cencora, Hinge Health, and Gilead – are likely more impervious to these cuts than owners of hospitals – particularly rural ones. Investors should scrutinize whether the relatively high dividends paid by some of these companies are worth the uncertain revenue impact of the Medicaid cuts.
Yahoo
08-07-2025
- Business
- Yahoo
Here's What to Expect From Cencora's Next Earnings Report
Valued at a market cap of $57.4 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions provider. The company specializes in pharmaceutical sourcing and distribution, providing a comprehensive range of services to healthcare providers and biopharmaceutical manufacturers throughout the U.S. and internationally. Cencora is slated to announce its fiscal Q3 2025 earnings results on Wednesday, Aug. 06. Ahead of the event, analysts forecast the company to report an adjusted EPS of $3.78, up 13.2% from $3.34 in the year-ago quarter. COR has surpassed Wall Street's bottom-line estimates in the past four quarterly reports. This Analyst Just Raised His Broadcom Stock Price Target by 70%. Should You Buy AVGO Now? Why Alibaba Stock Looks Like a Screaming Buy After Falling 27% From Its 2025 Highs 'Superintelligence' Takes Meta Platforms to Record Highs. Should You Buy META Stock Here? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2025, analysts project the prescription drug distributor to report adjusted EPS of $15.81, up 14.9% from $13.76 in fiscal 2024. Shares of Cencora have surged 35.9% over the past 52 weeks, outperforming both the S&P 500 Index's ($SPX) 11.9% rise and the Health Care Select Sector SPDR Fund's (XLV) nearly 7% decline over the same period. Shares of Cencora rose 4.7% on May 7 after the company raised its annual adjusted EPS forecast to a range of $15.70 to $15.95, surpassing analysts' average expectations. The upward revision was driven by strong demand for high-cost specialty medicines and GLP-1 weight-loss drugs, which significantly boosted revenue. Additionally, the company posted Q2 2025 adjusted profit of $4.42 per share and revenue of $75.5 billion, both exceeding analyst estimates. Analysts' consensus rating on Cencora stock is bullish, with an overall 'Strong Buy' rating. Among 15 analysts covering the stock, 12 recommend a "Strong Buy' and three give a "Hold" rating. This configuration is slightly more bullish than three months ago, with 11 analysts suggesting a "Strong Buy." As of writing, the stock is trading below the average analyst price target of $329. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Irish Times
05-07-2025
- Business
- Irish Times
Profits rise at BluePoint Pharmaceuticals but Cork firm warns of impact of tariffs
Cork-based pharmaceutical company BluePoint Pharmaceuticals has recorded post-tax profit of $12 million (€10.2 million) from its Irish operations and paid a $25 million dividend but warned that 'geopolitical risks' could impact its operations. Turnover at the Little Island firm grew to $218.66 million in the year ending September 2024, according to recently filed accounts with the Companies Registration Office. Turnover grew by just less than $650,000 in 2024, but this came after a $38 million increase in turnover in 2023 to $218.01 million. The company is ultimately owned by one of the largest pharmaceutical companies in the world, New York-listed Cencora Inc, formerly known as AmerisourceBergen Corporation. The parent company reported global turnover in 2024 of $294 billion. READ MORE With a US-based parent company, the company warned that US import tariffs post a risk to its operations noting the economic measures could affect its input costs or have 'adverse impacts' on demand for its products and supply chains. The company's directors warned that, among other factors, the uncertainty around the impact of tariffs, market volatility and 'slower economic growth or recession' could impact the business in 2025. Gross profits widened slightly in 2024 as costs of sales decreased but distribution and administrative expenses cut back pretax profits to within $50,000 of 2023. The company paid $1.83 million in tax in the financial year, compared with $1.94 million the year prior. Post-tax profits grew from $12.232 million in 2023, to $12.379 million in 2024. HP Pharmaceuticals Unlimited paid a $25 million dividend to shareholders, having not proposed a dividend since it made a $17 million shareholder payout in 2022. Staffing at the Cork business remained static at 36 in the period, though total payroll costs increased from $4.7 million in 2023, to $5.5 million in 2024, primarily driven by overall wages and salaries increasing by 17 per cent. Salary paid to directors stood at $513,000.
